Norge -
norsk -
Statens legemiddelverk
baclofen sintetica 2 mg/ ml
sintetica gmbh - baklofen - infusjonsvæske, oppløsning - 2 mg/ ml
Norge -
norsk -
Statens legemiddelverk
baclofen sintetica 0.5 mg/ ml
sintetica gmbh - baklofen - infusjonsvæske, oppløsning - 0.5 mg/ ml
Norge -
norsk -
Statens legemiddelverk
noradrenalin sintetica 0.1 mg/ ml
sintetica gmbh - noradrenalintartrat - infusjonsvæske, oppløsning - 0.1 mg/ ml
Norge -
norsk -
Statens legemiddelverk
noradrenalin sintetica 0.2 mg/ ml
sintetica gmbh - noradrenalintartrat - infusjonsvæske, oppløsning - 0.2 mg/ ml
Norge -
norsk -
Statens legemiddelverk
noradrenalin sintetica 1 mg/ ml
sintetica gmbh - noradrenalintartrat - konsentrat til infusjonsvæske, oppløsning - 1 mg/ ml
Norge -
norsk -
Statens legemiddelverk
ephedrine sintetica 50 mg/ ml
sintetica gmbh - efedrinhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml
Norge -
norsk -
Statens legemiddelverk
droperidol sintetica 0.5 mg/ ml
sintetica gmbh - droperidol - injeksjonsvæske, oppløsning - 0.5 mg/ ml
Den europeiske union -
norsk -
EMA (European Medicines Agency)
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
Den europeiske union -
norsk -
EMA (European Medicines Agency)
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
Den europeiske union -
norsk -
EMA (European Medicines Agency)
ertapenem sun
sun pharmaceutical industries (europe) b.v. - ertapenemnatrium - bakterielle infeksjoner - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 og 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.